A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial

Authors :: B. Massuti
Solange Peters
Delvys Rodriguez-Abreu
Margarita Majem
Lionel Falchero
Miklos Pless
Niels Reinmuth
Michael Mark
Linda Coate
E. De Maio
M. Cobo
H. Roschitzki-Voser
Rolf A. Stahel
R. von Moos
Sarah Danson
Urania Dafni
Mary O'Brien
Christoph C. Zielinski
Kurt G. Tournoy
Baktiar Hasan
Source :: Annals of Oncology. 29:viii498
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
Randomization
business.industry
Hematology
First line treatment
03 medical and health sciences
0302 clinical medicine
Denosumab
030220 oncology & carcinogenesis
Internal medicine
Medicine
030212 general & internal medicine
business
medicine.drug

Full Text Access

Tools